Document Detail


The impact of escalating conventional therapy in rheumatoid arthritis patients referred for anti-tumour necrosis factor-alpha therapy.
MedLine Citation:
PMID:  14657509     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To assess the impact of escalating conventional therapy in patients with RA who satisfy BSR/NICE criteria for biologics. METHODS: A total of 308 consecutive patients referred to a tertiary centre for biological therapy between January 1999 and February 2001 were studied prospectively. They were considered by their own consultant to have failed standard therapy. Prior to biologics, conventional therapy was escalated to include combination and parenteral methotrexate treatment. Patients were assessed at 12-weekly intervals for 1 yr and therapy was changed if response was not satisfactory. The subsequently released BSR/NICE biologic eligibility criteria were applied retrospectively. Response (disease activity, disability and quality of life) to escalated therapy in those patients who did or did not satisfy current eligibility criteria were compared. RESULTS: In total, 159 satisfied BSR/NICE criteria and would have been eligible for immediate treatment with biologics [DAS28 > 5.1, failed methotrexate (20 mg/week or lower dose owing to toxicity) and one other DMARD]; however, 93 of these responded to escalated conventional therapy and did not require biologics [significant improvement (P < 0.01) in disease activity, disability and quality of life]. However, mild disease activity (DAS28 < 3.2) was only achieved in 7% of these patients at 12 months. CONCLUSIONS: Although over half the patients who satisfied standard criteria for biologics responded satisfactorily to escalated therapy, only a minority achieved mild disease activity. The savings achieved by treating with conventional therapies need to be weighed against the risk of persistent disease activity.
Authors:
S J Bingham; M H Buch; A Tennant; P Emery
Related Documents :
24045349 - Are there differences between maori and non-maori patients undergoing primary total hip...
24659259 - Impact of bifurcation stent technique on clinical outcomes in patients with a medina 0,...
23599849 - Bedside teaching on time to disposition improves length of stay for critically-ill emer...
24440809 - Ondansetron combined with st36 (zusanli) acupuncture point injection for postoperative ...
21493209 - Laryngotracheoplasty to avoid tracheostomy in neonatal and infant subglottic stenosis.
24637979 - Effects of botulinum toxin type a for spastic foot in post-stroke patients enrolled in ...
4215329 - Influence of fractionation on acute and late reactions in vocal cord carcinoma.
16301459 - Use of bioglue surgical adhesive for brow fixation in endoscopic browplasty.
17296409 - Durability and cost-effectiveness of transurethral needle ablation of the prostate as a...
Publication Detail:
Type:  Journal Article     Date:  2003-12-01
Journal Detail:
Title:  Rheumatology (Oxford, England)     Volume:  43     ISSN:  1462-0324     ISO Abbreviation:  Rheumatology (Oxford)     Publication Date:  2004 Mar 
Date Detail:
Created Date:  2004-02-13     Completed Date:  2004-05-20     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  100883501     Medline TA:  Rheumatology (Oxford)     Country:  England    
Other Details:
Languages:  eng     Pagination:  364-8     Citation Subset:  AIM; IM    
Affiliation:
Rheumatology Research Unit, First Floor, Old Nurses Home, Leeds General Infirmary, Great George Street, Leeds LS1 3EX, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Adolescent
Adult
Aged
Aged, 80 and over
Antirheumatic Agents / economics,  therapeutic use*
Arthritis, Rheumatoid / drug therapy*,  economics
Drug Costs
Female
Humans
Male
Methotrexate / therapeutic use*
Middle Aged
Patient Selection*
Practice Guidelines as Topic
Prospective Studies
Quality of Life
Treatment Failure
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Chemical
Reg. No./Substance:
0/Antirheumatic Agents; 0/Tumor Necrosis Factor-alpha; 59-05-2/Methotrexate
Comments/Corrections
Comment In:
Rheumatology (Oxford). 2004 Sep;43(9):1199; author reply 1199-1200   [PMID:  15317963 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Does the road to muscle rejuvenation go through Notch?
Next Document:  Vasoactive intestinal peptide modulates proinflammatory mediator synthesis in osteoarthritic and rhe...